You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 20, 2024

CLINICAL TRIALS PROFILE FOR CLARAVIS

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for CLARAVIS

Subscribe to access the full database, or Try a Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00004188 ↗	Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma	Completed	National Cancer Institute (NCI)	Phase 3	2001-02-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: This randomized phase III trial is studying peripheral stem cell transplantation with treated peripheral stem cells following combination chemotherapy to see how well it works compared to peripheral stem cell transplantation with untreated peripheral stem cells following combination chemotherapy in treating patients with neuroblastoma.
NCT00004188 ↗	Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma	Completed	Children's Oncology Group	Phase 3	2001-02-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: This randomized phase III trial is studying peripheral stem cell transplantation with treated peripheral stem cells following combination chemotherapy to see how well it works compared to peripheral stem cell transplantation with untreated peripheral stem cells following combination chemotherapy in treating patients with neuroblastoma.
NCT00005576 ↗	Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma	Completed	National Cancer Institute (NCI)	Phase 1	2001-01-01	Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Combining monoclonal antibody therapy with sargramostim or interleukin-2 may kill more tumor cells. Phase I trial to study the effectiveness of monoclonal antibody therapy given with sargramostim and interleukin-2 in treating children with neuroblastoma who have just completed bone marrow or peripheral stem cell transplantation
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for CLARAVIS

Condition Name

Chart
Table

Condition Name for CLARAVIS
Intervention	Trials
Recurrent Neuroblastoma	8
Regional Neuroblastoma	6
Stage 4 Neuroblastoma	5
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for CLARAVIS
Intervention	Trials
Neuroblastoma	14
Ganglioneuroblastoma	4
Medulloblastoma	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for CLARAVIS

Trials by Country

Map
Table

Trials by Country for CLARAVIS
Location	Trials
United States	415
Canada	50
Australia	20
New Zealand	6
Puerto Rico	5
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for CLARAVIS
Location	Trials
California	17
Pennsylvania	16
Ohio	13
North Carolina	13
New York	13
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for CLARAVIS

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for CLARAVIS
Clinical Trial Phase	Trials
Phase 3	7
Phase 2	4
Phase 1/Phase 2	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for CLARAVIS
Clinical Trial Phase	Trials
Completed	10
Active, not recruiting	7
Recruiting	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for CLARAVIS

Sponsor Name

Chart
Table

Sponsor Name for CLARAVIS
Sponsor	Trials
National Cancer Institute (NCI)	21
Children's Oncology Group	8
Comprehensive Cancer Center of Wake Forest University	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for CLARAVIS
Sponsor	Trials
NIH	21
Other	10
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.